Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Low-Dose Pioglitazone in Patients With NASH (AIM 2) — Stella

Home/Type 2 Diabetes Mellitus (T2DM)/Low-Dose Pioglitazone in Patients With NASH (AIM 2)

View on ClinicalTrials.gov

Recruiting

Back to Type 2 Diabetes Mellitus (T2DM) trials

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University of Florida, Gainesville, Florida

Key details

Phase

Safety & dosing

Sponsor

University of Florida

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrollment target

~166 participants

Started

December 2020

Primary completion

August 2027

Age range

21 Years – 75 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.